

Supplementary material

Paszek E, Ząbczyk M, Natorska J, et al. Therapy with ticagrelor/prasugrel is associated with suppressed fibrinolysis and platelet activation as compared to clopidogrel in chronic coronary syndrome. Kardiol Pol. 2023.

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Statistically significant associations and correlations between platelet markers and clinical variables

sCD40L, ng/ml, median (interquartile range)		
Diabetes	No diabetes	P-value
1.26 (0.95–1.79)	0.97 (0.73–1.56)	0.03
Multivessel disease present	Multivessel disease absent	P-value
1.21 (0.89–1.79)	0.94 (0.68–1.36)	0.03
HbA1C (%)		P-value
Spearman Rho = 0.25		0.007
P-selectin, ng/ml, median (interquartile range)		
Diabetes	No diabetes	P-value
66.3 (52.3–90.6)	58.2 (45.8–68.3)	0.005
Obesity	No obesity	P-value

65.6 (54.1–84.0)	58.7 (43.2–79.1)	0.049
HbA1C (%)		<i>P</i>-value
Spearman Rho = 0.24		0.01

Abbreviations: sCD40L, soluble CD40 ligand; HbA1C, glycated hemoglobin

Table S2. Statistically significant correlations of plasminogen activator inhibitor-1 with other variables in the study group

PAI-1, ng/ml, median (interquartile range)		
Women	Men	<i>P</i>-value
36.1 (22.0–58.4)	25.5 (17.6–35.7)	0.01
Obesity present	No obesity	<i>P</i>-value
34.9 (25.0–53.2)	23.5 (17.9–34.6)	0.01
Hypertension	No hypertension	<i>P</i>-value
29.1 (19.7–41.3)	18.0 (13.0–21.9)	0.01
Diabetes	No diabetes	<i>P</i>-value
32.6 (20.9–52.4)	23.7 (17.3–36.9)	0.02
Spearman Rho		<i>P</i>-value
BMI	0.27	0.004
Lymphocyte count, 10 ³ /μl	0.22	0.02
Platelet count, 10 ³ /μl	0.19	0.04
HbA1C, %	0.22	0.02
sCD40L, ng/ml	0.32	<0.001

P-selectin, ng/ml	0.51	<0.001
Platelet factor 4, ng/ml	0.27	0.003

Abbreviations: BMI, body mass index; sCD40-L, soluble CD40 ligand; HbA1C, glycated hemoglobin